A team in Japan re-engineered zinc oxide, the harmless powder in sunscreen, into a material that emits near-infrared light from a gentle fingertip press. No power, no rare earths. Here's why it matters for medicine, bridges, and the rare-earth standoff.
Researchers at the University of Tokyo and Chiba University have developed ETE, a method that mass-produces hundreds of thousands of uniform cell-loaded capsules using only a bench-top vortex mixer and temperature control. A look at why it lowers the barrier for drug discovery and regenerative medicine, and how it compares with America's organoid industry.
A meniscus regeneration technology developed at Japan's Institute of Science Tokyo has been approved as Seibiscus, the country's first regenerative medicine product for meniscus injury. We explain how it uses a patient's own stem cells to repair the knee, what the Phase III trial showed, and how it compares with regenerative medicine ventures in South Korea and the US.
Kumamoto University has built a world-first device that kills anisakis parasites in raw fish using a 30,000-volt pulse lasting one-millionth of a second, without freezing or cooking. A look at the food-safety tech behind Japan's sashimi culture.
Kyoto University spinout Toregem Biopharma will begin Phase 2 trials of TRG035, the world's first tooth-regeneration drug, in summer 2026, dosing 24 children with congenital tooth agenesis. A pre-Series C round of ¥850 million brings cumulative funding, grants included, past ¥4.6 billion. A look at how Japan's university-biotech funding stack works, and why a super-aged society may produce this kind of innovation first.
Researchers at Kyoto University used Japan's near-total medical insurance database to trace esotropia (inward-turning eyes) cases from 2014 to 2019, the years smartphones swept the country. Incidence rose from 32.26 to 36.61 per 100,000 person-years; surgeries climbed from 3,061 to 3,743. The link with smartphone penetration is strong, the absolute rise is small.
After a stroke, the brain repairs itself for about two months, then stops. A team from Science Tokyo, TMIMS, Kyushu University and Freiburg University has identified the protein responsible, ZFP384, and developed an antisense drug that keeps the repair window open in mice. Published in Nature, the discovery could redraw what is possible for stroke survivors and other brain injuries.
Kissei Pharmaceutical reports 20 deaths among Japanese patients treated with Tavneos (avacopan), a vasculitis drug. Twenty-two cases of vanishing bile duct syndrome were identified, with 13 deaths. The FDA has proposed withdrawal; Europe's EMA is reviewing. Here is what is happening in Japan, the US, and Europe, and what it means for ANCA vasculitis patients.
NTT unveiled a world-first technique that uses just a smartphone camera to create illusions of softness and stickiness. How does this 'pseudo-haptics' approach differ from mainstream vibration motors and force feedback, and what problems does it solve?
On May 20, 2026, Japan added three ultra-expensive regenerative medicines to public insurance coverage: Amshepri (world's first iPS cell-derived drug, for Parkinson's), Akugo (stem cells for traumatic brain injury), and Zolgensma Intrathecal (gene therapy for SMA patients aged 2+). Prices range from 55 million yen ($352K) to 167 million yen ($1.06M). We explain why these drugs cost so much, how Japan's high-cost medical expense system shields patients, and whether prices might fall over time.
Hospital Facility Dogs, canine 'medical staff' that report to the same Japanese pediatric hospital five days a week, will grow to seven teams nationwide by fiscal 2027. From Shizuoka to Hyogo and Tsukuba, we look at how Shine On! Kids built this uniquely structured program, why each dog costs roughly ¥12 million (about $76,000) a year to operate, and how donations and corporate partnerships are filling the gap.
A Japanese research team led by Gakushuin University has discovered Mitorubin, a plant-derived compound that simultaneously increases mitochondrial quantity and function. The compound improved heart function in aged mice and extended median lifespan by about 40% in obese mice on a high-fat diet — a distinct approach from US longevity biotech, NAD supplements, and senolytics.
A Japanese team led by Prof. Takanori Takebe (Osaka & Science Tokyo) and Dr. Mureo Kasahara (National Center for Child Health and Development) plans the world's first pediatric clinical trial of UTOpiA, a bioartificial liver that perfuses blood through iPS-derived liver organoids. Animal trials showed 90% survival. How it compares with King's College London's HELP trial and Beijing's CiPS-BAL.
Researcher Yohei Kawai and Professor Shin Kaneko at Kyoto University's CiRA have established a way to induce helper T cells, the conductors of the immune system, from human iPS cells without mouse feeder cells. The paper ran in Molecular Therapy on January 20, 2026. Why this matters against the three structural limits of CAR-T therapy, and where Japan stands against Fate Therapeutics in the US and China's sheer trial volume.
Emergency transports for teen overdose in Tokyo have roughly tripled in five years, driven by over-the-counter medicines rather than illegal drugs. Japan's revised pharmaceutical law took effect on May 1, 2026, turning sales rules into binding obligations, but the isolation underneath remains unaddressed. Compared with the US fentanyl crisis and UK harm reduction.
A Tohoku University-UC Irvine team led by Prof. Kei Igarashi has discovered that dopamine in the entorhinal cortex drops to less than one-fifth of normal levels in Alzheimer's mice, driving memory loss. Published in Nature Neuroscience, the finding suggests Levodopa—a Parkinson's drug used for over half a century—could restore memory in Alzheimer's, opening a new path beyond the amyloid-beta hypothesis behind drugs like lecanemab.
Japan's gasoline has hit record highs, dialysis tubing is running out, and bathtubs can't be shipped. With 95% of crude oil coming from the Middle East, pivoting to the world's largest oil producer, America, seems like a perfect Win-Win. But refinery design, tanker size, the Panama Canal bottleneck, and an ironic naphtha yield problem all stand in the way. Here's why the obvious solution isn't simple.
A JAMSTEC-University of Tsukuba team has discovered self-replicating circular RNA replicons living in 70-80°C Japanese hot springs. These newly found members of the Obelisk superfamily, a mysterious RNA entity first described by Nobel laureate Andrew Fire in 2024, expand our view of RNA-based life and may offer fresh clues to the RNA world hypothesis on the origin of life.
Tokushima University researchers led by Prof. Tomohide Saio have unveiled OptoChaperone in JACS, a biohybrid tool that uses light to reversibly switch protein droplets on and off inside living cells. A look at how this Japanese breakthrough could accelerate ALS and Alzheimer's drug discovery, and how it compares with US and European condensate startups like Dewpoint Therapeutics and Nereid.
Panasonic has partnered with Kyoto University's iPS Cell Research Foundation to begin proof-of-concept trials for fully automating iPS cell establishment at Osaka's Nakanoshima Cross. The goal: slash per-patient costs from tens of millions of yen to around 1 million yen. How does Japan's approach compare with US rival Cellino's laser-driven biomanufacturing?